Search Results for agency_names:"Justice Department"

SpecGx LLC has applied to the Drug Enforcement Administration (DEA) to become an importer of certain controlled substances. The company aims to import these substances for the purpose of manufacturing Active Pharmaceutical Ingredients, which will then be distributed to its customers. However, this registration does not automatically allow for permit applications to import these substances to be approved; approval will be granted only if the business activities comply with specific legal requirements. Public comments or requests for a hearing regarding this application are open until April 28, 2025, and can be submitted electronically through the Federal eRulemaking Portal.

The document announces changes in the membership of the Information Warfare Research Project Consortium (IWRP) under the National Cooperative Research and Production Act of 1993. Several new companies have joined IWRP, while a number of others have withdrawn. The purpose of these notifications is to ensure that antitrust law applies in a way that limits claims to actual damages under certain conditions. Membership in the consortium remains open, and further notifications about changes will be filed in the future.

The Drug Enforcement Administration proposes to make seven fentanyl-related substances permanently controlled under Schedule I of the Controlled Substances Act. These substances, identified as dangerous opioids, are currently regulated under a temporary order due to their potential for abuse and health hazards. If this proposal is finalized, it would enforce permanent restrictions and legal penalties on the handling of these substances, which include para-chlorofentanyl and ortho-chlorofentanyl. The public is encouraged to submit comments on this rule by January 29, 2025.

The Department of Justice is inviting public comments on the proposed extension of an existing information collection by the FBI's Hazardous Devices School. This form, known as FD-731, is used to collect information on prospective students' identities and qualifications and to assess their security clearance status. The aim is to ensure these individuals have the necessary access to sensitive law enforcement facilities and information. The public comment period is open for 60 days, concluding on April 30, 2021, and the feedback will help evaluate and improve the collection process.

The Open Grid Alliance, Inc. (OGA) has updated its membership details, in line with the National Cooperative Research and Production Act of 1993. The notification, filed on October 11, 2024, indicates that Deutsche Telekom AG has withdrawn from the group. No other changes have occurred, and the group remains open to new members. Previous notifications about membership changes were also documented in the Federal Register on several occasions.

The Department of Justice, specifically the Drug Enforcement Administration (DEA), announced a notice for public commentary on its information collection request related to the National Forensics Laboratory Information System. This system gathers drug analysis data from non-federal labs to improve accuracy on drug information. The DEA is seeking approval from the Office of Management and Budget (OMB) for a three-year extension without changes to the existing collection, which involves responses from various agencies and businesses. Public comments on the burden and utility of this data collection are being accepted until March 3, 2025.

Patheon API Services Inc. has applied to the Drug Enforcement Administration (DEA) to become a registered bulk manufacturer of certain controlled substances. This registration is intended to support the clinical trials of their customers. Interested parties are invited to submit comments or objections electronically through the Federal eRulemaking Portal by June 17, 2025. They may also request a hearing on the application by the same date.

The Drug Enforcement Administration (DEA) has announced that Cosmic Light LLC, located in Boulder, Colorado, has applied to become a registered bulk manufacturer of marihuana, classified as a Schedule I controlled substance. This registration would allow them to produce bulk materials needed to develop pharmaceutical products for research purposes. Interested parties have until April 30, 2021, to submit comments or objections regarding this application. The DEA will review this application following its established regulations to ensure compliance and prevent misuse.

The Drug Enforcement Administration (DEA) issued an order to revoke Maria Dewitt's registration to handle controlled substances because she lacks the necessary authorization in Texas. Dewitt did not have a required prescriptive authority delegation agreement with a physician, which is essential for an advanced practice registered nurse in Texas to manage controlled substances. The administrative law judge upheld this decision, noting that without state authorization, Dewitt could not maintain her DEA registration. Consequently, her registration was revoked, and any further applications for registration in Texas were denied.

In a decision by the Drug Enforcement Administration (DEA), Dr. Michael W. Carlton's Certificate of Registration was revoked due to inappropriate prescribing practices. The DEA found that Dr. Carlton issued 40 prescriptions for controlled substances without establishing a proper doctor-patient relationship and without conducting necessary physical exams, which violated federal and Arizona state laws. Dr. Carlton argued that his practice was standard at the outpatient treatment center where he worked, but the DEA's investigation and expert testimony showed that his actions fell below the standard of care. Consequently, the revocation was seen as necessary to protect public interest.